Microsoft word - antibiotic and anthelmintics_20091102.doc
Fonterra Co-operative Group Limited
Private Bag 92032 Auckland Fonterra Centre 9 Princes Street Auckland, New Zealand Telephone: +64 9 374 9000
All Fonterra manufacturing specifications are developed to meet New Zealand Government, importing country Government regulations and, when requested, customer specific requirements. The New Zealand Food Safety Authority (NZFSA) regulations require all milk produced on New Zealand dairy farms meet the regulatory requirements as specified under the Animal Products Act 1999. The approved criteria (DPC2: Approved Criteria for Farm Dairies) under this Act stipulates the following: Veterinary Medicines Where milking animals are treated with veterinary medicines:
The use is appropriate, and recognised for the condition being treated in milking animals;
The farm dairy occupier accurately follows the instructions on the label, or provided by a veterinarian; and
The farm dairy occupier uses the medicine appropriately, to avoid violative residues.
The milk from animals which have been treated with veterinary medicines is withheld for the time specified by the supplier of the remedy, or the veterinarian. The withheld milk is not used for human consumption. When mastitic animals are treated with veterinary medicines, milk is withheld from all quarters for the specified withholding time. Raw Milk Testing Programme Under the National Chemical Contaminants (NCCP) programme administered by the NZFSA, regular random and targeted sampling and testing of raw milk for a wide range of chemical residues operates throughout each year. The NCCP includes monitoring for residues of antibiotics and anthelmintics. In addition to the NCCP Fonterra operates a two tiered system for testing raw milk for antibiotics.
All tanker loads are screened for antibiotics prior to delivery for further processing.
Daily samples of milk are obtained from each supplying dairy farm at time of milk collection. Samples are tested by the NZFSA approved laboratories for the presence of inhibitory substances using microbial inhibition assays such as the Delvo test with a sensitivity of 0.003 IU/ml benzyl penicillin randomly at least 4 times per month.
The information and/or opinions contained in this attestation are current as of the date of issue of this attestation and this attestation is based on information and facts known to Fonterra Co-operative Group Limited, its subsidiaries and affiliates (collectively, “Fonterra”) on such date of issue. The information and/or opinions contained in this attestation may be changed at any time without notice and Fonterra does not assume any obligation to review or update such information and/or opinions. Fonterra and its agents, suppliers and distributors make no representations or warranties of any kind with respect to the information and/or opinions contained in this attestation including, but not limited to, any representation or warranty as to the accuracy, adequacy or completeness of such information and/or opinions or that such information and/or opinions are suitable for your intended use. All queries with respect to this attestation are to be addressed to you account manager or your customer service account executive.
Fonterra Co-operative Group Limited Fonterra Co-operative Group Limited
Private Bag 92032 Auckland Fonterra Centre 9 Princes Street Auckland, New Zealand Telephone: +64 9 374 9000
Detection of residues in a supplier's milk results in immediate suspension of supply until the next milk consignment is confirmed as being fit for purpose. Very heavy penalties are imposed on all milk tested positive. Each consignment of milk is tested for a 12 month period after a positive result is detected.
In addition to this, every batch of milk powder is tested using the IDF 57 test method. Yours faithfully FONTERRA CO-OPERATIVE GROUP LIMITED
Bo Patel Manager, Global Market Access
The information and/or opinions contained in this attestation are current as of the date of issue of this attestation and this attestation is based on information and facts known to Fonterra Co-operative Group Limited, its subsidiaries and affiliates (collectively, “Fonterra”) on such date of issue. The information and/or opinions contained in this attestation may be changed at any time without notice and Fonterra does not assume any obligation to review or update such information and/or opinions. Fonterra and its agents, suppliers and distributors make no representations or warranties of any kind with respect to the information and/or opinions contained in this attestation including, but not limited to, any representation or warranty as to the accuracy, adequacy or completeness of such information and/or opinions or that such information and/or opinions are suitable for your intended use. All queries with respect to this attestation are to be addressed to you account manager or your customer service account executive.
Tetraparesi spastica: descrizione di un caso clinico S. Sale, P. Cabras, A. Guido, A. Mura , F. Angioi, G. Spano. Istituto di Clinica Odontoiatrica (Dir. P. F. Lugliè)-Università La piccola paziente R.E. di anni 13, si è presentata presso il nostro istituto, accompagnata dai genitori, in quanto affetta da tetraparesi spastica, lamentando gravi difficoltà respiratorie imputabili a malocclus
FATE DECISIONS DURING NEURAL CREST ONTOGENY Chaya Kalcheim Department of Medical Neurobiology, Hebrew University of Jerusalem and Hadassah The dorsal neural tube first generates neural crest cells that exit the neural primordium following an epithelial-to-mesenchymal conversion to become sympathetic ganglia, Schwann cells, dorsal root sensory ganglia and melanocytes of the skin
Fonterra Co-operative Group Limited 
Fonterra Co-operative Group Limited